Duke Street Bio announces first patient dosed in Phase I trial with DSB2455, a next deneration PARP1 selective inhibitor for the treatment of solid tumours
December 3, 2024
December 3, 2024
September 26, 2024
September 24, 2024
May 15, 2024
May 14, 2024
May 8, 2024
May 6, 2024
February 21, 2024
February 20, 2024
October 9, 2025
Alithea Genomics, a leader in next-generation transcriptomic solutions, today announced the commercial launch of MERCURIUS™ Spheroid DRUG-seq, a novel...
October 6, 2025
AmpliCell® Cytokines enable cell expansion optimization, batch-to-batch consistency and easy transition from research to manufacturing TheraPEAK® 293-...
September 30, 2025
New offering to debut at 32nd ESGCT Congress, October 7–10 in Seville, Spain PromoCell GmbH, a leading global manufacturer of primary human cells and ...
Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225